Additive Value of Biomarkers and Echocardiography to Stratify the Risk of Death in Heart Failure Patients with Reduced Ejection Fraction
Joint Authors
Luigi Temporelli, Pier
Falletta, Calogero
Clemenza, Francesco
Klersy, Catherine
Agnese, Valentina
Bellavia, Diego
Di Gesaro, Gabriele
Minà, Chiara
Romano, Giuseppe
Dini, Frank Lloyd
Rossi, Andrea
Raineri, Claudia
Turco, Annalisa
Traversi, Egidio
Ghio, Stefano
Source
Cardiology Research and Practice
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-05-02
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background.
Risk stratification is a crucial issue in heart failure.
Clinicians seek useful tools to tailor therapies according to patient risk.
Methods.
A prospective, observational, multicenter study on stable chronic heart failure outpatients with reduced left ventricular ejection fraction (HFrEF).
Baseline demographics, blood, natriuretic peptides (NPs), high-sensitivity troponin I (hsTnI), and echocardiographic data, including the ratio between tricuspid annular plane excursion and systolic pulmonary artery pressure (TAPSE/PASP), were collected.
Association with death for any cause was analyzed.
Results.
Four hundred thirty-one (431) consecutive patients were enrolled in the study.
Fifty deaths occurred over a median follow-up of 32 months.
On the multivariable Cox model analysis, TAPSE/PASP ratio, number of biomarkers above the threshold values, and gender were independent predictors of death.
Both the TAPSE/PASP ratio ≥0.36 and TAPSE/PASP unavailable groups had a three-fold decrease in risk of death in comparison to the TAPSE/PASP ratio <0.36 group.
The risk of death increased linearly by 1.6 for each additional positive biomarker and by almost two for women compared with men.
Conclusions.
In a HFrEF outpatient cohort, the evaluation of plasma levels of both NPs and hsTnI can contribute significantly to identifying patients who have a worse prognosis, in addition to the echocardiographic assessment of right ventricular-arterial coupling.
American Psychological Association (APA)
Falletta, Calogero& Clemenza, Francesco& Klersy, Catherine& Agnese, Valentina& Bellavia, Diego& Di Gesaro, Gabriele…[et al.]. 2019. Additive Value of Biomarkers and Echocardiography to Stratify the Risk of Death in Heart Failure Patients with Reduced Ejection Fraction. Cardiology Research and Practice،Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1145884
Modern Language Association (MLA)
Falletta, Calogero…[et al.]. Additive Value of Biomarkers and Echocardiography to Stratify the Risk of Death in Heart Failure Patients with Reduced Ejection Fraction. Cardiology Research and Practice No. 2019 (2019), pp.1-9.
https://search.emarefa.net/detail/BIM-1145884
American Medical Association (AMA)
Falletta, Calogero& Clemenza, Francesco& Klersy, Catherine& Agnese, Valentina& Bellavia, Diego& Di Gesaro, Gabriele…[et al.]. Additive Value of Biomarkers and Echocardiography to Stratify the Risk of Death in Heart Failure Patients with Reduced Ejection Fraction. Cardiology Research and Practice. 2019. Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1145884
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1145884